Chemical–biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target

Scholarly Works

• Okai, C. A.; Danquah, B. D.; Lartey, M.; Oppong, M. B.; Amponsah, S. K.; Adutwum, L. A.; Opuni, K. F. M. Analytical Methods in Pharmacoproteomics: A Systematic Review. Pharmacoproteomics; Springer Nature Switzerland, 2024; pp 49–75. doi:10.1007/978-3-031-64021-6_4
• Araujo, S. C.; de Angelo, R. M.; Barbosa, H.; Costa-Silva, T. A.; Tempone, A. G.; Lago, J. H. G.; Honorio, K. M. Identification of inhibitors as drug candidates against Chagas disease. European journal of medicinal chemistry 2022, 248, 115074. doi:10.1016/j.ejmech.2022.115074
• Lemke, C.; Jílková, A.; Ferber, D.; Braune, A.; On, A.; Johe, P.; Zíková, A.; Schirmeister, T.; Mareš, M.; Horn, M.; Gütschow, M. Two Tags in One Probe: Combining Fluorescence- and Biotin-based Detection of the Trypanosomal Cysteine Protease Rhodesain. Chemistry (Weinheim an der Bergstrasse, Germany) 2022, 28, e202201636. doi:10.1002/chem.202201636
• Hansen, A. H.; Christensen, H. B.; Pandey, S. K.; Sergeev, E.; Valentini, A.; Dunlop, J.; Dedeo, D.; Fratta, S.; Hudson, B. D.; Milligan, G.; Ulven, T.; Ulven, E. R. Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2. ChemMedChem 2021, 16, 3326–3341. doi:10.1002/cmdc.202100356
• Kourbeli, V.; Chontzopoulou, E.; Moschovou, K.; Pavlos, D.; Mavromoustakos, T.; Papanastasiou, I. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases. Molecules (Basel, Switzerland) 2021, 26, 4629. doi:10.3390/molecules26154629
• Doherty, W.; Adler, N.; Butler, T. J.; Knox, A. J. S.; Evans, P. Synthesis and optimisation of P3 substituted vinyl sulfone-based inhibitors as anti-trypanosomal agents. Bioorganic & medicinal chemistry 2020, 28, 115774. doi:10.1016/j.bmc.2020.115774
• Cannalire, R.; Stefanelli, I.; Cerchia, C.; Beccari, A. R.; Pelliccia, S.; Summa, V. SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. International journal of molecular sciences 2020, 21, 5707. doi:10.3390/ijms21165707
• da Silva Santos, S.; de Araujo, R. V.; Giarolla, J.; Seoud, O. A. E.; Ferreira, E. I. Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review. International journal of antimicrobial agents 2020, 55, 105906. doi:10.1016/j.ijantimicag.2020.105906
• Dehghanpoor, S.; Sadeghi, B.; Mosslemin, M. H. Green Nano-Silica Sulfuric Acid-Catalyzed Synthesis of New 6-Amino-8-aryl-7-(benzenesulfonyl)-2-(hydroxymethyl)-pyrano[3,2-b]pyran-4(8H)-one Derivatives. Russian Journal of Organic Chemistry 2019, 55, 1957–1960. doi:10.1134/s107042801912025x
• Villalta, F.; Rachakonda, G. Advances in preclinical approaches to Chagas disease drug discovery. Expert opinion on drug discovery 2019, 14, 1161–1174. doi:10.1080/17460441.2019.1652593
• Abyar, E.; Sadeghi, B.; Mosslemin, M. H. Synthesis of Novel 2-Amino-7-Methyl-4-Aryl-3-(Phenylsulfonyl)Pyrano[4,3-b]Pyran-5(4H)-One Derivatives in the Presence TiCl4 Supported on Kaolin as a Nano Catalyst. Polycyclic Aromatic Compounds 2019, 41, 920–928. doi:10.1080/10406638.2019.1628784
• Sadeghi, B. Synthesis of novel 6-amino-2-(hydroxymethyl)-8-aryl-7-(phenylsulfonyl)pyrano[3,2-b]pyran-4(8H)-one derivatives catalyzed by nano-cellulose-OSO3H. Research on Chemical Intermediates 2019, 45, 4897–4906. doi:10.1007/s11164-019-03870-9
• Field, M. C.; Horn, D.; Fairlamb, A. H.; Ferguson, M. A. J.; Gray, D. W.; Read, K. D.; De Rycker, M.; Torrie, L. S.; Wyatt, P. G.; Wyllie, S.; Gilbert, I. H. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nature reviews. Microbiology 2017, 15, 217–231. doi:10.1038/nrmicro.2016.193
• Apt, W. Treatment of Chagas' disease. American Trypanosomiasis Chagas Disease 2017, 113, 751–771. doi:10.1016/b978-0-12-801029-7.00032-0
• Hallenbeck, K.; David, T.; Renslo, A. R.; Arkin, M. R. Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery. Current topics in medicinal chemistry 2016, 17, 4–15. doi:10.2174/1568026616666160719163839
• Goupil, L.; Ivry, S. L.; Hsieh, I.; Suzuki, B. M.; Craik, C. S.; O’Donoghue, A. J.; McKerrow, J. H. Cysteine and Aspartyl Proteases Contribute to Protein Digestion in the Gut of Freshwater Planaria. PLoS neglected tropical diseases 2016, 10, e0004893. doi:10.1371/journal.pntd.0004893
• Begolo, D.; Clayton, C. Comprehensive Analysis of Parasite Biology: From Metabolism to Drug Discovery; Wiley, 2016; pp 1–39. doi:10.1002/9783527694082.ch1
• Janovy, J. J.; Esch, G. W. doi:10.1002/9781118884799.ch15
• Bermúdez, J. M.; Davies, C.; Simonazzi, A.; Real, J. P.; Palma, S. D. Current drug therapy and pharmaceutical challenges for Chagas disease. Acta tropica 2015, 156, 1–16. doi:10.1016/j.actatropica.2015.12.017
• McShan, D.; Kathman, S. G.; Lowe, B.; Xu, Z.; Zhan, J.; Statsyuk, A. V.; Ogungbe, I. V. Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain. Bioorganic & medicinal chemistry letters 2015, 25, 4509–4512. doi:10.1016/j.bmcl.2015.08.074

Explore citations to this article at